Amitriptyline is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Not applicable. The sponsor with the most trials is The Third Affiliated hospital of Zhejiang Chinese Medical University (1). The most-studied condition is Bladder Pain Syndrome.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
EA for BPS: An RCT and Study for Central Mechanism
NCT05279963 · ClinicalTrials.gov ↗ · Bladder Pain Syndrome
|
Not applicable | Recruiting | The Third Affiliated hospital of Zhejiang Chinese Medical University | China |
|
Treatment of Post-Stroke Central Pain
NCT07593313 · ClinicalTrials.gov ↗ · Central Post-Stroke Pain
|
Not applicable | Recruiting | Nanchong Central Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
11 single-substance products containing Amitriptyline on the HPRA medicines list.
+ 8 more German shortage notices.
| Lead sponsor | Trials |
|---|---|
| The Third Affiliated hospital of Zhejiang Chinese Medical University | 1 |
| Nanchong Central Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Amitriptyline as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The Third Affiliated hospital of Zhejiang Chinese Medical University (1) and Nanchong Central Hospital (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 11 single-substance products containing Amitriptyline, for example Amitriptyline 25 mg Film-Coated Tablets (Clonmel Healthcare Ltd). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 14 entries for Amitriptyline: 14 German notices. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Amitriptyline works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Amitriptyline works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Amitriptyline (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.